Overview

Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations

Status:
Completed

Trial end date:
2018-02-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to explore the combination of Ataluren and ivacaftor as a treatment for patients with a specific cystic fibrosis mutation

Phase:

Phase 4

Details

Lead Sponsor:

University of Alabama at Birmingham

Treatments:

Ivacaftor